Novartis to keep making malaria drugs even if orders dry up, Reuters reports

Novartis (NVS) will continue making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding cuts, Lutz Hegemann, its president of global health, tells Reuters in an interview, Jennifer Rigby reports. “We are not going to be the bottleneck,” Hegemann says, adding that “We are not going to produce based on demand, because we know that these medicines are needed, and we need to be creative in finding ways to get them from the factory to patients.”